To specifically redirect lymphocytes endogenously expressing NKG2D or engineered with an NKG2D-based CAR to tumor cells with low or absent NKG2D ligand expression, we previously described different designs for bispecific molecules, which all reflect the structure and approximate size of IgG antibodies, but can simultaneously interact with NKG2D and the tumor-associated antigen ErbB2 (HER2) via respective single-chain fragment variable (scFv) antibodies connected by hinge, CH2, and CH3 domains of IgG4 [27]. This evidence concerns the gene KLRK1 and neoplasm.